iSpecimen Inc. (ISPC)
ISPC trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1558569/000121390026038607/0001213900-26-038607-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ISPC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001558569 |
| SEC industry code | Services-Commercial Physical & Biological Research |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.9M |
| Net income | -$10.5M |
| Operating income | -$9.0M |
| Net margin | -543.7% |
| Operating margin | -465.4% |
| Revenue growth | -79.2% |
| Cash | $6.9M |
| Total assets | $9.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of one year from the date these unaudited condensed financial statements are issued." | 10-Q 2026-08-14 |
| Cash and burn | $4.4M cash; operating cash flow -$1.8M a quarter. | Report 2026-06-30 |
| Shares outstanding | 2,518,590 (2026-08-14); 5,539,345 a year earlier; 9,065,483 three years earlier. 1y figure adjusted for splits (1-for-40 overall); 3y figure adjusted for splits (1-for-800 overall). | Cover page 2026-08-14 |
| Reverse splits, 3 years | 2; latest 1-for-40 on 2026-04-28 | Source 2026-04-28 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-06-04 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-06-01 |
| Auditor | Bush & Associates CPA LLC, Las Vegas, Nevada, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-03-11 |
| Late filings, 12 months | 2 NT notices | NT 10-Q 2026-05-18 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 5,426,567 shares at the 2026-11-13 price; the latest SEC cover count is 2,518,590 as of 2026-08-14. One of the two share counts is stale. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $152K | -$1.4M | -$690K | $4.4M | No debt tags | $466K | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $156K | -$2.3M | -$3.4M | $2.8M | No debt tags | $1.0M | 10-Q 2026-05-18 |
| Q4 2025 2025-12-31 | $52K | -$5.0M | -$917K | $6.9M | No debt tags | $1.9M | 10-K 2026-04-01 |
| Q3 2025 2025-09-30 | $107K | -$2.8M | -$2.0M | $2.8M | No debt tags | $3.4M | 10-Q 2025-11-17 |
| Q2 2025 2025-06-30 | $713K | -$1.0M | -$192K | $589K | No debt tags | $5.9M | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $1.1M | -$1.7M | -$1.1M | $783K | No debt tags | $8.1M | 10-Q 2026-05-18 |
| Q4 2024 2024-12-31 | $1.5M | -$6.0M | -$3.6M | $1.9M | No debt tags | $9.3M | 10-K 2026-04-01 |
| Q3 2024 2024-09-30 | $2.7M | -$1.4M | -$1.1M | $1.8M | $864K | $10.4M | 10-Q 2025-11-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B4 | 2026-08-07 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-04-01 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-08-14 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-09 |
| Latest proxy PROXY STATEMENT | PRE 14A | 2026-10-30 |
Source: SEC EDGAR submissions feed, 334 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -19.0% |
| 1 month | -39.0% |
| 3 months | -71.3% |
| Year to date | -93.7% |
| 1 year | -97.3% |
| From 52-week high | -97.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Commercial Physical & Biological Resarch
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BIAF | bioAffinity Technologies Inc. | $2.00 | -9.09% | $3.6M |
| ONMD | OneMedNet Corp | $4.86 | -8.99% | $29.2M |
| MXCT | MaxCyte Inc. | $1.18 | -0.84% | $121.8M |
| NRC | NRC Health | $26.33 | -0.87% | $558.8M |
| OABI | OmniAb Inc. | $4.89 | -0.41% | $713.3M |
| ABSI | Absci Corporation | $7.47 | -11.54% | $1.3B |
| ICLR | ICON plc | $191.40 | -1.67% | $14.7B |
| CRL | Charles River Laboratories International Inc. | $335.52 | -0.72% | $16.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier